|1.||Bauer, M: 2 articles (06/2000 - 06/2000)|
|2.||Koster, A: 2 articles (06/2000 - 06/2000)|
|3.||Hetzer, R: 2 articles (06/2000 - 06/2000)|
|4.||Mertzlufft, F: 2 articles (06/2000 - 06/2000)|
|5.||Kuppe, H: 2 articles (06/2000 - 06/2000)|
|6.||Hansen, R: 2 articles (06/2000 - 06/2000)|
|7.||Cosseddu, Domenico: 1 article (03/2015)|
|8.||Vitale, Corrado: 1 article (03/2015)|
|9.||Berutti, Silvia: 1 article (03/2015)|
|10.||Migliardi, Marco: 1 article (03/2015)|
06/01/2013 - "We recommend performing the following tests if DOAC intake is unknown: dabigatran-associated bleeding risk is minimized or can be neglected if thrombin time, Hemoclot test, or Ecarin clotting time is normal. "
04/01/2008 - "Bleeding complications and monitoring of the ecarin clotting time imposes limitations. "
10/01/2002 - "New monitoring tools, such as the ecarin clotting time (ECT), might further reduce bleeding risks. "
11/01/1999 - "If ecarin clotting time, the most suitable monitor for hirudin activation, is not available, we would prefer to give r-hirudin in repeated boluses to avoid major bleeding complications in cardiac surgery patients on CVVH."
11/15/1995 - "After infusion of ecarin following hirudin administration, the hirudin blood level dropped sharply, reaching significantly reduced values, and bleeding stopped. "
03/01/2005 - "[Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia]."
01/01/2005 - "Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization."
06/01/2000 - "Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II."
05/01/2001 - "Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass."
06/01/2000 - "A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II : adaptation of the ecarin clotting time to the act II device."
10/01/1975 - "The effect of ecarin- defibrinating enzyme isolated from Echis carinatus - on experimental arterial thrombosis."
01/01/1998 - "We studied the use of the Ecarin Clotting Time (ECT) as a predictive assay of the antithrombotic effects of argatroban in a new tissue factor-dependent model of venous thrombosis and a model of arterial thrombosis in the rat. "
|4.||Disseminated Intravascular Coagulation
01/01/1988 - "These split products of prothrombin are convertible by ecarin to meizothrombin 1 and 2. A positive ecarin test can be also due to acarboxylated precursors which are released during increased proteosynthesis triggered by consumption coagulopathy."
06/01/1986 - "Disseminated intravascular coagulation (DIC) was produced by an infusion of a prothrombin activator (Echis carinatus venom; 30 minutes; 0.5 NIH thrombin equivalent U/kg) in mongrel dogs (Echis group, n = 7). "
|5.||Venous Thrombosis (Deep-Vein Thrombosis)
|4.||Thromboplastin (Tissue Factor)
|5.||Prothrombin (Factor II)
|7.||Biological Markers (Surrogate Marker)
|1.||Cardiopulmonary Bypass (Heart-Lung Bypass)
|2.||Renal Dialysis (Hemodialysis)